

# Starpharma Holdings Limited

ASX Small to Mid Caps

## Stock Exchange Listing

ASX: SPL, OTCQX: SPHRY

## Company profile

Starpharma Holdings Limited is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

The Company's lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement for a VivaGel® coated condom with SSL International plc (LSE:SSL), owners of the world's leading condom brand, Durex®.

More broadly the company is exploring dendrimer opportunities in materials science applications including water remediation.

[Click here to access the company's 2009 Annual Report \(PDF 1,14MB\)](#)

## Recent Developments

In February 2010 SPL signed a collaborative research and development program with Eli Lilly and Company under which Starpharma's dendrimer drug delivery technology will be applied to enhance compounds in Lilly's human pharmaceutical portfolio.

In March 2010, Starpharma announced positive clinical trial results showing the active ingredient in VivaGel® SPL7013 Gel was safe and well tolerated in a study of sexually active women following application twice daily for 14 days.

Additionally, following the completion of an institutional share placement in November 2009 Starpharma will pursue clinical testing of VivaGel® for Bacterial Vaginosis (BV), the most common vaginal infection worldwide. The Company will commence trials of VivaGel® as a BV treatment in 2010.

## Significant Contractual Arrangements

In February 2010 Starpharma signed a collaborative research and development program with Eli Lilly and Company under which Starpharma's dendrimer drug delivery technology will be applied to enhance compounds in Lilly's human pharmaceutical portfolio.

In November 2009 Starpharma signed a research and collaboration agreement between its wholly owned US subsidiary, DNT Inc, and a prominent, multi-billion dollar US-based agricultural chemicals company.

In May 2009 signed a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company to develop new animal health products with enhanced properties using Starpharma's dendrimer technology.

In September 2008 Starpharma signed a full licence agreement with SSL International, owners of the world's leading condom brand, Durex®, for the commercialisation of the VivaGel®-coated condom.

This profile is provided by Starpharma Holdings Limited; ASX takes no responsibility for the information included. Participation in this event should not be taken as an endorsement by ASX of the company.

Starpharma, PO Box 6535, St Kilda Road Central, Victoria 8008, Australia

**Telephone:** +61 3 8532 2700

**Email:** [info@starpharma.com](mailto:info@starpharma.com)


**Website:** [www.starpharma.com](http://www.starpharma.com)



# Starpharma Holdings Limited

ASX Small to Mid Caps

## Intellectual Property/products/product development programs



\*Condom coating: accelerated development program

## Future Outlook

Starpharma remains focused on advancing the development of our lead product VivaGel®, advancing other applications of our dendrimer technology platform, and finding new partners to increase revenue as well as strengthening and building upon our existing international partnerships.

We are also working towards commencing further clinical studies of VivaGel®, including a phase 2 efficacy study in bacterial vaginosis, during 2010.

This profile is provided by Starpharma Holdings Limited; ASX takes no responsibility for the information included. Participation in this event should not be taken as an endorsement by ASX of the company.